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cate that the CorPath robotic system can be successfully used to treat
PAD. Technical and clinical procedural success was obtained in all 20
patients and no device-related peri-procedural adverse events were
reported. Further studies are needed to conﬁrm the results and
elucidate their impact on outcomes.
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BACKGROUND The aim of this review is to consider evidence for the
Multilayer Flow Modulator (MFM) device in management patients
with complex thoracoabdominal aortic aneurysm (TAAA) or
dissection.
METHODS A methodical search of all health databases was con-
ducted from January 2008 to 2015 for health related and biomedical
science literature, pertaining to the MFM. Primary outcome was
aneurysm-related survival. Secondary outcomes were all-cause sur-
vival, stroke, spinal cord ischemia, renal impairment and branch
vessel patency
RESULTS A total of 15 studies (3 prospective studies, 3 observational
reviews and 9 case reports) were included. The mean age of patients
was 68.85years (þ/-12.34 years), mean aneurysm diameter was 6.67cm
(1.57cm). Technical success reported in 15 studies was 77.2 %.
Aneurysm related survival at one year was 78.7% (3.92%). One year
all-cause survival was 53.7 % (3.94%). There were no reported cases
of spinal cord ischemia or renal insult.
CONCLUSIONS The MFM appears safe in management of TAAA, once
operators abide to its Indications for Use. Since the MFM is a new
technology, there is paucity of long-term follow-up data, a lack of
comparative studies and a requirement for randomized clinical trials
and continued assessment.
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BACKGROUND The Multilayer ﬂow Modulator (MFM) increases
visceral branch outﬂow velocities by up to 8% in TAAA. The phantom
Streamliner conﬁguration generates double renal outﬂow percentage
increase. Moreover, there are differences in ﬂow lamination between
anatomical and ballerina outﬂow conﬁgurations to the iliac arterial
tree.
METHODS Out of 13 patients managed by Phantom Streamlinear
conﬁguration, of which 10 were males with mean age of 69.57þ/-9.8
years. Mean aneurysm diameter was 6.4cm with mean aneurysm
length of 26.96cm. All were ASA IV. There were four Crawford type II,
IV with AAA, seven supra/juxta-renal AAA and two complicated type B
dissection.
RESULTS Numbers of side branches covered were 61 branches with
mean of 4.7 side branch per case. Total numbers of stent used were 63
with mean of 6.25 MFM stents per case. There were no aneurysm-
related death, no paraplegia nor stroke, no renal impairment and noloss of branch patency. Quantile-Quantile plot demonstrated that
mean aortic length; diameter and thrombus are statically lower at post
op from pre op with alpha level of 5%. Moreover, there was evidence
of postoperative lower thrombus volume with no change in total
volume from pre to post. Length and diameter demonstrated the most
signiﬁcant change. The aortic lumen barely hits any signiﬁcance.
There were a decrease in mean diameter, length and thrombus
signifying a different mechanism in remodeling and laminar ﬂow.
CONCLUSIONS Phantom Streamliner is a promising technology, safe
with physiological modulation of TAAA with off the shelf availability
and must be utilized under strict IFU.
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BACKGROUND Controversy exists regarding the best revasculariza-
tion strategy for femoro-popliteal disease. We performed a network
meta-analysis of randomized controlled trials (RCTs) in patients un-
derwent peripheral endovascular intervention for femoro-popliteal
lesion to seek relative clinical outcomes of drug-coated balloon (DCB),
drug-eluting stent (DES), or bare-metal nitinol stent (BMS) compared
with balloon angioplasty (BA).
METHODS MEDLINE/PubMed, Cochrane CENTRAL, EMBASE, and
ClinicalTrials.gov were searched for RCTs comparing two treatment
modalities among DCB, DES, BMS, or BA in patients with femoro-
popliteal disease. Mixed treatment comparison model generation was
performed to directly and indirectly compare DCB, DES, and BMS on
outcomes including target lesion revascularization (TLR), primary
patency, death, and amputation at 12 and 24 month with BA. Odds
ratios with 95% conﬁdence intervals (OR [95% CIs]) were generated
with random-effect models to compare outcomes.
RESULTS Our meta-analysis included 15 RCTs with 2,843 patients that
were randomized to DCB (n¼752), DES (n¼288), BMS (n¼581), or BA
(n¼1,222). The mean age was 68.315.4, 65% were male, 41% had
coronary artery disease, 84% had hypertension, 41% had diabetes
mellitus, 11% had re-stenotic lesion, 32% had total occlusion, 7% had
critical limb ischemia, baseline ankle-brachial index of 0.680.38, and
baseline lesion length of 68.772.0 mm. At 12 month, DCB signiﬁ-
cantly reduced the risk of TLR (OR 0.29 [95% CI 0.13-0.56]), and DCB
(OR 0.41 [95% CI 0.22-0.74]) and BMS (OR 0.61 [95% CI 0.36-1.00])
signiﬁcantly improved primary patency compared with BA. DES had a
trend toward improvement in primary patency and TLR compared
with BA.
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patency at 12-months compared with BA with a trend toward
improved outcomes for DES and BMS compared with BA. Head to head
comparison for DCB vs stenting strategies is warranted.
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BACKGROUND Endovascular occlusion of blood vessels represents a
key component of interventional therapy. While coils are most
commonly used, vessel occlusion is generally not achieved immedi-
ately and may necessitate a large number of devices. It has been
suggested that endovascular plugs may overcome these limitations;
however, immediate and durable occlusion remains a challenge with
plugs as well. This study evaluates a newly designed endovascular
occlusion system (ArtVentive EOS).
METHODS The EOS combines a nitinol scaffold with an impermeable
membrane made of expanded polytetraﬂuoroethylene (ePTFE). The
scaffold offers sufﬁcient radial force to create a sufﬁcient vessel wall
apposition and minimize post-deployment migration. Eight test de-
vices were deployed in the left renal arteries of four miniature swine.
Angiography was performed 1 and 10 minutes after device implanta-
tion. Follow-up angiography was obtained on day 30 (four devices)
and day 60 (four devices) prior to devices harvesting for histological
evaluation and biocompatibility assessment.
RESULTS All test devices were deployed as intended, and produced
complete and immediate vessel-occlusion. No clinical complications
were observed in the animals throughout the study course. No
recanalization, acute or chronic device migration was observed in
the renal arteries. Complete and durable vessel-occlusion without
any sign of recanalization and evidence of distal ischemia (renal
atrophy) was observed in all EOS devices during the follow-up
period.
CONCLUSIONS The EOS is a safe and reliable device resulting in im-
mediate and durable vessel occlusion in the renal arterial circulation
and evidenced by complete end organ ischemia.
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BACKGROUND Occasionally inferior vena cava (IVC) ﬁlters can
become occluded leading to signiﬁcant lower extremity morbidity.
Percutaneous endovenous intervention (PEVI) with different modal-
ities is the procedure of choice. Stents have been successfully used in
maintaining patency of the IVC ﬁlter which is often contracted and
ﬁbrosed. In this report we discuss the outcome of placement of
Wallstents in IVC ﬁlters at 28 5 months of follow-up.
METHODS We placed Wallstents in 37 patients who had presented
with chronic IVC ﬁlter occlusion. These stents were placed within or
adjacent to the occluded IVC ﬁlter. The patients had presented with
chronic bilateral lower extremity obstructive symptoms. Bilateral
popliteal venous access sites were used in all patients as the initial
approach. In 24 patients catheter directed thrombolysis was given
with t-PA for 18-28 hours. All patients were placed on indeﬁniteanticoagulation post-procedurally with rivaroxaban in 19 patients and
apixaban in 18. Aspirin at 81 mg was given to 34 of 37 patients for 6
months.
RESULTS The patients’ average age was 66 7 years. The duration
from IVC implantation was 5.7 2 years. Crossing the IVC ﬁlter was
from the popliteal vein in 31 patients and the right internal jugular
vein in 6. The adjacent space between the ﬁlter and IVC wall was
crossed in 9 and through the ﬁlter in 28 patients. Following placement
of a Wallstent, post dilatation to burst pressure was performed by a
high pressure balloon. The average diameter and length of the Wall-
stents were 16 0.7 X 739 mm. Within hours of PEVI, patients’
symptoms substantially improved. The stents were patent at a mean
follow-up of 28 5 months. There was no bleeding or recurrent
venous thromboembolic disease (VTE) during the procedure or at
follow-up.CONCLUSIONS The results demonstrate that juxta or intra IVC ﬁlter
stenting with a Wallstent is safe and effective in chronic IVC ﬁlter
occlusions. Furthermore administration of new oral anticoagulants
plus low-dose aspirin would prevent further IVC obstruction and VTE.
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